Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.56 |
| ▸ | ATR | Q13535 | 10/20 | 0.56 |
| ▸ | PRKDC | P78527 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | USP7 | Q93009 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934795 | 1.00 | ADORA1 (0.56) | ADORA1ADORA2AATRPRKDCATM | |
| SCHEMBL6696482 | 0.93 | PIK3CG (0.55) | ADORA1ADORA2AATRPRKDCATM | |
| SCHEMBL32688927 | 0.90 | ATR (0.66) | ATRPRKDC | |
| SCHEMBL6701248 | 0.90 | ATR (0.66) | ATRPRKDC | |
| SCHEMBL2931488 | 0.85 | NEK2 (0.64) | ATRPRKDCATMPIK3CG | |
| SCHEMBL27328541 | 0.85 | KMT2A (0.59) | ADORA1ADORA2AATRPRKDCATM | |
| SCHEMBL12198431 | 0.84 | ATR (0.56) | ADORA1ADORA2AATRPRKDCMEN1 | |
| SCHEMBL29886432 | 0.82 | ATR (0.57) | ADORA1ADORA2AATRPRKDC | |
| SCHEMBL29886145 | 0.82 | ATR (0.57) | ADORA1ADORA2AATRPRKDC | |
| SCHEMBL6704802 | 0.81 | PIK3CG (0.51) | ADORA1ADORA2AATRPRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | claimed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | claimed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | claimed |
| WO-2023162995-A1 | NOVEL COELENTERAZINE DERIVATIVES | 国立大学法人電気通信大学 | 2023-08-31 | — | — | WO | disclosed |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | UNIVERSITY CATHOLIQUE DE LOUVAIN (BE) | 2004-02-19 | — | — | US | disclosed |
| EP-1292580-A1 | PYRAZINE AND IMIDAZOPYRAZINE DERIVATIVES AS ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001087853-A1 | ARYL-SUBSTITUTED N,N-HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PREPARATION AND THEIR USE IN THERAPEUTICS AND DIAGNOSTICS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034225-A1 | Aryl-substituted n, n-heterocyclic compounds, method for their preparationand their use in therapeutics and diagnostics | NOX5, NOX4, CD22 | ADORA1 1806/4885ADORA2A 480/4885ATR 4853/4885 |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | ADORA1 3661/4885ADORA2A 2090/4885ATR 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.